Publications Repository

Publications Repository

View item 
  •   Home
  • ICR Divisions
  • Clinical Studies
  • View item
  • Home
  • ICR Divisions
  • Clinical Studies
  • View item
JavaScript is disabled for your browser. Some features of this site may not work without it.

Outcome of uterine sarcoma patients treated with pazopanib: A retrospective analysis based on two European Organisation for Research and Treatment of Cancer (EORTC) Soft Tissue and Bone Sarcoma Group (STBSG) clinical trials 62043 and 62072.

Thumbnail
View/Open
Accepted version (557.6Kb)
Date
2016-07
ICR Author
van der Graaf, Wilhelmina
Judson, Ian
Author
Benson, C
Ray-Coquard, I
Sleijfer, S
Litière, S
Blay, J-Y
Le Cesne, A
Papai, Z
Judson, I
Schöffski, P
Chawla, S
Gil, T
Piperno-Neumann, S
Marréaud, S
Dewji, MR
van der Graaf, WTA
Show allShow less
Type
Journal Article
Metadata
Show full item record
Abstract
Background Uterine sarcomas are a group of mesenchymal tumours comprising several histologies. They have a high recurrence rate following surgery, modest outcome to systemic therapy, and poor overall survival. Pazopanib is a multi-targeted tyrosine kinase inhibitor approved for non-adipocytic advanced soft tissue sarcomas (STS). Here we investigated whether response to pazopanib in patients with uterine sarcomas differs from that of patients with non-uterine sarcomas.Patients and methods Uterine sarcoma patients were retrieved from all soft tissue sarcoma patients treated with pazopanib in EORTC Phase II (n=10) and Phase III (PALETTE) (n=34) studies. Patient and tumour characteristics, response, progression free and overall survival data were compared.Results Forty-four patients with uterine sarcoma were treated with pazopanib. The majority of patients had uterine leiomyosarcoma (LMS) (n=39, 88.6%) with high grade tumours (n=37, 84.1%) compared to 54.8% (n=164) in the non-uterine population. The median age was 55years (range 33-79) and median follow up was 2.3years. Uterine patients were heavily pre-treated, 61.3% having ≥2 lines of chemotherapy prior to pazopanib compared to 40.8% in the non-uterine population. Five patients (11%), all LMS, had a partial response (95% CI 3.8-24.6). Median progression free survival (PFS) 3.0months (95% CI 2.5-4.7) in uterine versus 4.5 (95% CI 3.7-5.1) in non-uterine STS. Median overall survival (OS) was 17.5months (95% CI 11.1-19.6), longer than the non-uterine population, 11.1months (95% CI 10.2-12.0) (p=0.352).Conclusions Despite heavy pre-treatment, pazopanib shows signs of activity in patients with uterine sarcoma with the similar outcomes to patients with non-uterine STS.
URI
https://repository.icr.ac.uk/handle/internal/324
DOI
https://doi.org/10.1016/j.ygyno.2016.03.024
Collections
  • Clinical Studies
Subject
Humans
Leiomyosarcoma
Sarcoma
Uterine Neoplasms
Sulfonamides
Pyrimidines
Protein Kinase Inhibitors
Prognosis
Survival Rate
Retrospective Studies
Adolescent
Adult
Aged
Aged, 80 and over
Middle Aged
Female
Young Adult
Research team
Clinical and Translational Sarcoma
Sarcoma Clinical Trials
Language
eng
Date accepted
2016-03-18
License start date
2016-07
Citation
Gynecologic oncology, 2016, 142 (1), pp. 89 - 94

Browse

All of ICR repositoryICR DivisionsBy issue dateAuthorsTitlesPublication TypesThis collectionBy issue dateAuthorsTitlesPublication Types
  • Login
  • Registered office: The Institute of Cancer Research, 123 Old Brompton Road, London, SW7 3RP
    A Charity, Not for Profit. Company Limited by Guarantee.
    Registered in England No. 534147. VAT Registration No. GB 849 0581 02.